Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zilebesiran in mild-to-moderate hypertension
NCT04936035Phase 2Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Conjugated siRNA, Chemically Modified siRNA
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of zilebesiran in hypertension (HTN) (5 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: 24-hour Mean Systolic Blood Pressure Assessed by ABPM at 3 months. Started Jul 2021; status: completed.
02
Drugs
zilebesiran
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT04936035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04936035.